The Seattle biotech teaching biologics to read the room - drugs that switch on in the tumor and off everywhere else.
In a lab on Eastlake Avenue, a protein is making a decision. It is holding two things at arm's length - a powerful immune-signaling molecule and a marker that only shows up on certain cells. It can grab one or the other, but never both at once. This small, deliberate hesitation is the entire business of Bonum Therapeutics. The company has built a way to make medicine that waits. Wait for the right signal, then act. No signal, no action.
That sounds modest. It is not. The history of biologic drugs - the antibodies and cytokines that can be astonishingly effective against cancer - is also a history of collateral damage. The good stuff works everywhere, including where you'd rather it didn't. Bonum's whole proposition is that a drug should know where it is.
Cytokines are some of the most potent tools in immunology. Interleukin-2 can rev up the immune system to attack a tumor. Interferon-alpha can do the same. The catch, which oncologists have lived with for decades, is that these molecules don't carry a map. Dose a patient with enough cytokine to matter, and you also get fever, vascular leak, and a long list of side effects that cap how much you can safely give.
The field's workaround has been to aim better - antibody-drug conjugates, bispecifics, masked antibodies. Each is a clever attempt to point a powerful drug at a tumor. Most share a quiet limitation: once switched on, they tend to stay on. A drug that activates near a tumor is good. A drug that also keeps working after it drifts into healthy tissue is a problem looking for a place to happen.
Bonum's founders had already spent years on exactly this question. The answer they kept circling back to wasn't a sharper aim. It was reversibility - a drug that could switch off as readily as it switched on.
Here is the part that sounds made up. In 2022, Roche bought a Seattle company called Good Therapeutics for $250 million upfront. The prize was a single program: a conditionally active, PD-1-regulated IL-2 - a cytokine wired to turn on only near the right immune cells. A clean validation of an idea.
Good Therapeutics' founder, John Mulligan, had a reading of that deal that most people miss. Roche bought one drug. It did not buy the method for making more of them. So Mulligan spun out a new company, carried over the broader platform and - this is the unusual bit - essentially the entire team. He called it Bonum, Latin for "good." The naming was not subtle. Neither was the bet: if one conditionally active drug is worth $250 million to Roche, the engine that produces them is worth building twice.
Mulligan is not a first-timer. Across roughly three decades he has founded Blue Heron Biotechnology, Glycostasis (sold to Eli Lilly), Good Therapeutics (Roche), and now Bonum. The pattern is consistent: build a platform, prove it on one program, let a larger company validate it with a check. Bonum is the fourth swing.
Spun out of Good Therapeutics in 2022, right after Roche's $250M acquisition of Good's lead program.
The founding scientific team transferred over almost intact - protein engineers, cancer immunologists, molecular biologists.
$93M Series A within about two months of launch, led by the same syndicate that backed Good - plus Roche's own venture fund.
The technology has a name that does it no favors with poets: the dual-binding antibody, or DBA, platform. The mechanism, though, is almost elegant. A single engineered domain can bind to two different proteins - an effector, like a cytokine, or a marker protein found on diseased cells. The trick is the word "or." It can hold one at a time, never both.
Play that out. When the drug is near a cell displaying the marker, the marker wins the tug-of-war, the cytokine is released, and the medicine goes to work. When the drug drifts somewhere without the marker, the cytokine stays clamped and quiet. Move away from the marker and the drug deactivates again. This is what "fully reversible" means in Bonum's literature - not a one-way switch, but a dimmer that tracks its surroundings in real time.
In 2025 the U.S. Patent and Trademark Office agreed the mechanism was genuinely novel, granting U.S. Patent No. 12,303,567, with patents also issued in the UK and Australia. The claims cover specific marker-effector pairs - LRRC15 with interferon-alpha, PD-L1 with interferon-alpha, PD-1 with IL-2 - the building blocks of the pipeline.
The lead program straps interferon-alpha to a sensor for LRRC15, a marker enriched in the tumor microenvironment. The aim is an oncology drug that floods a tumor with immune-activating signal while staying dark in healthy tissue. Behind it sit programs built on IL-2, IL-12 and TGF-beta, and ambitions that reach past cancer into autoimmunity, metabolic disease and pain - anywhere powerful biology has been held back by its lack of restraint.
Roche acquires Good Therapeutics for $250M upfront for its conditionally active PD-1-regulated IL-2 program.
John Mulligan launches Bonum, retaining the broader platform and the founding team.
Codon Capital, Roche Venture Fund, RiverVest, 3x5 Partners, Digitalis and Vivo Capital back the launch.
Bonum upgrades its Seattle offices and expands hiring as it pushes its lead cancer program forward.
USPTO issues Patent No. 12,303,567 on the dual-binding antibody mechanism; UK and Australia follow.
Biotech is a field where conviction is measured in capital, because the products take years to speak for themselves. By that measure the conditionally-active idea has been heard. Roche put down $250M for one program. Investors then put $93M behind the platform that produced it. Across the two companies, roughly $373M in total funding has chased one stubborn premise: that a drug with an off switch is worth more than a drug without one.
Bars scaled to the $373M cumulative figure. Team size shown for scale, not dollars. Figures from public funding announcements.
~30 years in drug discovery. Founded Blue Heron, Glycostasis (Lilly) and Good Therapeutics (Roche). MIT undergrad, Stanford-trained.
25+ years in biologics research, steering the science behind the dual-binding platform.
25+ years in drug development and business strategy.
20+ years building biologics - the engine room of a dual-binding antibody company.
Bonum's stated mission is to harness well-characterized biological pathways in a targeted way - to maximize patient benefit while improving safety. Stripped of the corporate cadence, it's a bet that the bottleneck in modern medicine isn't always finding a powerful mechanism. Often we already have one. The bottleneck is control - using that mechanism without poisoning the patient who needs it.
That reframing is why the platform's reach extends past oncology. The same off-switch logic that keeps a cytokine quiet outside a tumor could, in principle, keep an immune-modulating drug quiet outside an inflamed joint, or a metabolic drug quiet outside the tissue it's meant to reach. Bonum lists oncology, autoimmunity, metabolic disorders and pain as targets. Whether all of those pan out is the open question that every clinical trial exists to answer.
None of this is approved yet. Bonum is clinical-stage, its lead program is still proving itself, and biology has a long record of humbling confident platforms. A skeptic is right to note that a granted patent and a funded syndicate are not the same as a drug that helps a patient. They are promissory notes, not results.
But the underlying idea is the kind that tends to outlast the company that first proves it. If medicines can reliably be made to act only where disease lives, the safety ceiling that has capped some of the most promising biology for decades starts to lift. That's not a marketing claim - it's the specific, testable thing Bonum is building toward, one program at a time.
Return to that protein on Eastlake Avenue, still holding two things at arm's length, still deciding. A few years ago, that pause was a slide in a pitch deck and a clause in a patent application. Today it is a granted U.S. patent, a $93M war chest, a roughly 28-person team, and a lead program inching toward the clinic. The hesitation got funded.
What it hasn't done yet is reach a patient. That is the line Bonum still has to cross, and the only one that ultimately counts. But the wager is clear, and it's a good one to watch: that the smartest thing a drug can do is sometimes nothing at all - until it's standing in exactly the right place.